Search Medical Condition
Please enter condition
Please choose location

Lincoln, Rhode Island Clinical Trials

A listing of Lincoln, Rhode Island clinical trials actively recruiting patient volunteers.

RESULTS

Found (164) clinical trials

A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression

This is an open-label (the researchers and participants know the treatment the participant is receiving) long-term extension study. The study will consist of 2 open-label Phases: 4-week Induction phase (if applicable) and Open-Label Optimization/Maintenance phase (variable). Participants will enter the study Induction Phase from ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ...

Phase

0.0 miles

Learn More »

Long-term Study of Lemborexant in Insomnia Disorder

This is a long-term (approximately 1 year), multicenter, randomized, controlled, double-blind, parallel group study of two doses of lemborexant and placebo in approximately 900 male or female participants with insomnia disorder. Approximately 40% of participants will be age 65 years or older. The study will last a maximum of 60 ...

Phase

0.0 miles

Learn More »

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

Phase

0.0 miles

Learn More »

Vortioxetine 5 10 and 20 mg Relapse Prevention Study in Adults With Major Depressive Disorder

The drug being tested in this study is called vortioxetine. Vortioxetine is being tested for the prevention of relapse in adults with major depressive disorder (MDD) who respond to daily treatment with vortioxetine. This study will look at relapse rates of MDD in people who take vortioxetine. The study will ...

Phase

0.39 miles

Learn More »

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

This is a randomized, open-label, parallel group study of patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder and their caregivers. Study will consist of a paired patient and caregiver. Patients will receive routine treatment, which may include oral antipsychotics or paliperidone palmitate, as directed by their treating physician. Caregivers for ...

Phase N/A

0.39 miles

Learn More »

Three Doses of Lasmiditan (50 mg 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Subjects will be asked to treat a migraine attack with study drug on an outpatient basis. Subjects will be provided with a dosing card containing a dose for initial treatment and a second dose to be used for rescue or recurrence of migraine. Each subject's study participation will consist of ...

Phase

0.39 miles

Learn More »

Study on the Efficacy Safety and Tolerability of Cariprazine Relative to Placebo in Patients With Bipolar I Depression

This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 mg/day or 3 mg/day compared to placebo for treatment of the depressive episode in patients with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

Phase

0.39 miles

Learn More »

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.

Phase

0.39 miles

Learn More »

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

This is a double-blind, randomized, placebo-controlled, parallel-arm study in subjects with DLB or PDD who have RBD. Subjects who meet the randomization criteria will be randomized 1:1 to receive Nelotanserin or placebo for 28 days during the double-blind period.

Phase

0.39 miles

Learn More »

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD). This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. The trial is being conducted in subjects with treatment ...

Phase

0.39 miles

Learn More »